Population Health Perspectives: Examining Infertility
Jeffrey Dunn, PharmD, MBA, discusses how assisted reproductive technologies (ART) are evaluated, implemented and improved through comparison trials, comprehensive program design and consideration of social determinants of health, while also addressing unmet needs to enhance patient outcomes and access to fertility treatments.
EP. 1: The Importance of Clinical Trials in Infertility
September 27th 2024Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.
Watch
EP. 2: Coverage Considerations for ART Protocols
September 27th 2024The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.
Watch
EP. 3: Overcoming Barriers in ART
October 4th 2024Jeffrey Dunn, Pharm.D., MBA, discusses how the overall issues for assisted reproductive technologies (ARTs) encompass a range of challenges, including access, affordability, efficacy and ethical considerations, and the need for continued research and improvement in treatment protocols
Watch
